{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:09:18Z","timestamp":1783537758574,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508103"],"award-info":[{"award-number":["2023YFC2508103"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508101"],"award-info":[{"award-number":["2023YFC2508101"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373496"],"award-info":[{"award-number":["82373496"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173420"],"award-info":[{"award-number":["82173420"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Plaque psoriasis (PP) is a chronic immune-mediated inflammatory disease driven by dysregulation of the IL-23\/Th17\/IL-17 axis. Although IL-17A-targeted biologics achieve robust clinical efficacy, the systemic immune remodeling accompanying successful treatment remains incompletely understood. We performed longitudinal immune profiling in seven patients with PP before treatment and after achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) following secukinumab therapy. Circulating T-cell subsets, programmed cell death protein 1 (PD-1)-expressing populations, cutaneous lymphocyte antigen-positive (CLA+) T cells, and plasma cytokines were analyzed by flow cytometry and multiplex assays. Ex vivo responses to the PD-1 agonist peresolimab were further evaluated in an independent cohort. At baseline, patients exhibited reduced frequencies of regulatory T cells compared with healthy controls. Following PASI 90, circulating Th17 and Th2 cell frequencies increased despite minimal sustained changes in plasma cytokine levels, suggesting dissociation between effector T-cell expansion and soluble inflammatory mediators during IL-17A blockade. Circulating CD4+CLA+ T cells were partially restored, and treatment was accompanied by increased frequencies of PD-1-expressing CD4+ T-cell subsets, which were inversely associated with disease activity over time. Ex vivo PD-1 engagement selectively suppressed IL-17A-producing CD4+ T cells while largely preserving IFN-\u03b3 production. These findings suggest that clinical improvement during IL-17A blockade is accompanied by coordinated immune remodeling rather than generalized systemic immunosuppression and that PD-1 signaling may contribute to restraining Th17 effector function during therapeutic response.<\/jats:p>","DOI":"10.1093\/cei\/uxag037","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:26:00Z","timestamp":1782818760000},"source":"Crossref","is-referenced-by-count":0,"title":["PD-1 engagement and circulating Th17 effector activity during secukinumab treatment in plaque psoriasis"],"prefix":"10.1093","volume":"220","author":[{"given":"Mengmeng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Huashan Hospital Fudan University, Shanghai Institute of Dermatology , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujiao","family":"Feng","sequence":"additional","affiliation":[{"name":"Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai ,","place":["China"]},{"name":"Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexiang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital Fudan University, Shanghai Institute of Dermatology , Shanghai ,","place":["China"]},{"name":"Department of Dermatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital Fudan University, Shanghai Institute of Dermatology , Shanghai ,","place":["China"]},{"name":"Department of Dermatology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shen","sequence":"additional","affiliation":[{"name":"Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai ,","place":["China"]},{"name":"Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9335-7022","authenticated-orcid":false,"given":"Zhenghua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Huashan Hospital Fudan University, Shanghai Institute of Dermatology , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2026070813463261600_uxag037-B1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026070813463261600_uxag037-B2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"2026070813463261600_uxag037-B3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026070813463261600_uxag037-B4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cei\/uxac069","article-title":"A sharp decrease of Th17, CXCR3+-Th17, and Th17.1 in peripheral blood is associated with an early anti-IL-17-mediated clinical remission in psoriasis","volume":"210","author":"Tsiogkas","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2026070813463261600_uxag037-B5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2026070813463261600_uxag037-B6","doi-asserted-by":"crossref","first-page":"e2023134","DOI":"10.5826\/dpc.1302a134","article-title":"Investigation of the PD-1\/PD-L1 expression in the lesional skins of patients with psoriasis","volume":"13","author":"Emre","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"2026070813463261600_uxag037-B7","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.3390\/jcm12134179","article-title":"The impact of biologic treatment on PD-1\/PD-L1 pathway disturbances in psoriasis","volume":"12","author":"Adamczyk","year":"2023","journal-title":"J Clin Med"},{"key":"2026070813463261600_uxag037-B8","doi-asserted-by":"crossref","first-page":"103339","DOI":"10.1016\/j.jaut.2024.103339","article-title":"PD-1 antibody interactions with Fc gamma receptors enable PD-1 agonism to inhibit T cell activation-therapeutic implications for autoimmunity","volume":"149","author":"Feng","year":"2024","journal-title":"J Autoimmun"},{"key":"2026070813463261600_uxag037-B9","doi-asserted-by":"crossref","first-page":"eadd4947","DOI":"10.1126\/sciimmunol.add4947","article-title":"Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases","volume":"8","author":"Suzuki","year":"2023","journal-title":"Sci Immunol"},{"key":"2026070813463261600_uxag037-B10","doi-asserted-by":"crossref","first-page":"e70079","DOI":"10.1111\/exd.70079","article-title":"Changes in the immune profile and chromatin accessibility of peripheral regulatory T cells in psoriasis patients before and after treatment with biologics","volume":"34","author":"Zhang","year":"2025","journal-title":"Exp Dermatol"},{"key":"2026070813463261600_uxag037-B11","doi-asserted-by":"crossref","first-page":"104985","DOI":"10.1016\/j.ebiom.2024.104985","article-title":"High-dimensional profiling of regulatory T cells in psoriasis reveals an impaired skin-trafficking property","volume":"100","author":"Lee","year":"2024","journal-title":"EBioMedicine"},{"key":"2026070813463261600_uxag037-B12","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.3390\/jcm10173880","article-title":"The defect in regulatory T cells in psoriasis and therapeutic approaches","volume":"10","author":"Kanda","year":"2021","journal-title":"J Clin Med"},{"key":"2026070813463261600_uxag037-B13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/ard.62.6.561","article-title":"Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept","volume":"62","author":"Zou","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2026070813463261600_uxag037-B14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jaci.2021.02.019","article-title":"Optimal human pathogenic TH2 cell effector function requires local epithelial cytokine signaling","volume":"148","author":"Calise","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026070813463261600_uxag037-B15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jid.2023.06.194","article-title":"Genomic profiling of the overlap phenotype between psoriasis and atopic dermatitis","volume":"144","author":"Kim","year":"2024","journal-title":"J Invest Dermatol"},{"key":"2026070813463261600_uxag037-B16","doi-asserted-by":"crossref","first-page":"e14958","DOI":"10.1111\/exd.14958","article-title":"Development of IL-17A inhibitor-induced atopic dermatitis-like rash in psoriasis patients: insights into immune shift","volume":"33","author":"Li","year":"2024","journal-title":"Exp Dermatol"},{"key":"2026070813463261600_uxag037-B17","doi-asserted-by":"crossref","first-page":"652613","DOI":"10.3389\/fimmu.2021.652613","article-title":"The translational relevance of human circulating memory cutaneous lymphocyte-associated antigen positive T cells in inflammatory skin disorders","volume":"12","author":"de Jes\u00fas-Gil","year":"2021","journal-title":"Front Immunol"},{"key":"2026070813463261600_uxag037-B18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/1346-8138.15278","article-title":"Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab","volume":"47","author":"Morita","year":"2020","journal-title":"J Dermatol"},{"key":"2026070813463261600_uxag037-B19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.5114\/ada.2021.112274","article-title":"PD1\/PD-L1 pathway in psoriasis and psoriatic arthritis: a review","volume":"38","author":"Adamczyk","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"key":"2026070813463261600_uxag037-B20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4155\/bio-2019-0090","article-title":"Receptor occupancy measurement of anti-PD-1 antibody drugs in support of clinical trials","volume":"11","author":"Fu","year":"2019","journal-title":"Bioanalysis"},{"key":"2026070813463261600_uxag037-B21","doi-asserted-by":"crossref","first-page":"114907","DOI":"10.1016\/j.celrep.2024.114907","article-title":"PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity","volume":"43","author":"Saad E","year":"2024","journal-title":"Cell Rep"},{"key":"2026070813463261600_uxag037-B22","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"2026070813463261600_uxag037-B23","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070813463261600_uxag037-B24","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.coi.2025.102641","article-title":"Checkpoint agonists-immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis","volume":"96","author":"Baroz","year":"2025","journal-title":"Curr Opin Immunol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxag037\/68651503\/uxag037.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag037\/68651503\/uxag037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/220\/1\/uxag037\/68651503\/uxag037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:46:40Z","timestamp":1783532800000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/doi\/10.1093\/cei\/uxag037\/8722067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxag037","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"uxag037"}}